Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL: USL255 (Qudexy XR) in refractory partial-onset seizures
NCT01142193Phase 3Completed
- Sponsor
- Upsher-Smith Laboratories
- Start
- May 2010
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of topiramate in focal onset seizure, sponsored by Upsher-Smith Laboratories. Started May 2010; status: completed.
02
Drugs
topiramate
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT01142193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01142193.